Back Pain News and Research RSS Feed - Back Pain News and Research

Back pain is a very common problem affecting almost all individuals at some point in their lives. Back pain most commonly affects the lower back although it can be felt anywhere along the spine. An individual may experience aching, tension and stiffness that lasts for only a few days or weeks, or these symptoms may continue for many months or even years.

In most cases, back pain does not have a specific or serious cause and is often referred to as 'non-specific' pain. However, the pain can be triggered or worsened by, for example, a poor sitting or standing posture or bending or lifting incorrectly.

The use of painkillers and keeping active is often sufficient for the condition to resolve within 12 weeks. If back pain lasts longer than this, in which case it is termed chronic pain, an individual should visit their doctor. If the back pain is accompanied by any one of a fever, unexplained weight loss, swelling in the back, chest pain, leg pain, loss of bladder or bowel control, inability to pass urine, or pain that is worse at night, then medical help should be sought immediately. These are termed 'red flag symptoms' and could be a sign of something more serious such as rheumatoid arthritis, a slipped disc or osteoporosis.

People can reduce their chance of developing back pain by engaging in regular exercise, particularly swimming or walking, taking care to bend from the knees and hips rather than the back and maintaining a good posture.
Insomnia is a marker for increased risk of back pain, say University of Haifa researchers

Insomnia is a marker for increased risk of back pain, say University of Haifa researchers

Having trouble sleeping? Then you are nearly one-and-a-half times more likely to eventually suffer from back pain, according to a new study conducted by the University of Haifa. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Revolutionising back pain treatments: an interview with Dr Kieran O’Sullivan

Back pain is exceptionally common. In fact, to not experience back pain at some point of your life would be thoroughly abnormal. Experiencing back pain is like becoming tired or becoming sad; we don’t necessarily like it, but it’s perfectly common. [More]
Boston Scientific Precision Spectra SCS System provides sustained relief for low back pain patients

Boston Scientific Precision Spectra SCS System provides sustained relief for low back pain patients

New retrospective data evaluating the Boston Scientific Corporation Precision Spectra Spinal Cord Stimulator (SCS) System demonstrate that the device provided sustained, highly significant relief of low back pain 12 months after implantation. [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE wins Gold 2014 International MarCom Award for SI Joint Patient Community website

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, won the Gold 2014 International MarCom Award for its SI Joint Patient Community website and an Honorable Mention for the SI Buddy Patient Networking Program. [More]
New study examines efficacy of brace application for treatment of spinal compression fractures

New study examines efficacy of brace application for treatment of spinal compression fractures

Compression fractures in the spine due to osteoporosis, a common condition causing progressive bone loss and increased fracture risk, are especially common in older women. A new study appearing in the December 3rd issue of the Journal of Bone & Joint Surgery found that patients who wore a brace as treatment for a spinal compression fracture had comparable outcomes in terms of pain, function and healing when compared to patients who did not wear a brace. [More]
St. Mary's Medical Center adds Mazor Renaissance robot-assisted system to Spine Center

St. Mary's Medical Center adds Mazor Renaissance robot-assisted system to Spine Center

Dignity Health St. Mary's Medical Center has added the Mazor Robotics Renaissance computer-generated guidance system to its multidisciplinary Spine Center. St. Mary's is the only hospital in the Bay Area to exclusively offer this state-of-the-art technology for spine surgery. [More]

Benvenue Medical's Luna 360 System receives FDA clearance for spinal fusion treatment of DDD

Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, today announced that the company's Luna 360 Interbody Fusion System has received 510(k) clearance from the U.S. Food and Drug Administration for spinal fusion treatment of symptomatic degenerative disc disease (DDD). [More]
Two medical research bodies announce new research centre to tackle musculoskeletal disorders

Two medical research bodies announce new research centre to tackle musculoskeletal disorders

A major new research centre to tackle the impact of musculoskeletal disorders on people's ability to work has been announced by two leading medical research bodies. [More]
Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
BioElectronics to present innovative chronic pain therapy at OTC Pharma Asia Conference

BioElectronics to present innovative chronic pain therapy at OTC Pharma Asia Conference

BioElectronics Corporation, the maker of advanced consumer and healthcare medical devices announced today that its Executive Vice President, Dr. Deepak Kotak has been invited to present BioElectronics' innovative chronic pain therapy at the OTC Pharma Asia Conference, on Tuesday, March 3, 2015 in Singapore. [More]
Smokers are three times more likely to develop chronic back pain than nonsmokers, study finds

Smokers are three times more likely to develop chronic back pain than nonsmokers, study finds

If you want to avoid chronic back pain, put out the cigarette. A new Northwestern Medicine study has found that smokers are three times more likely than nonsmokers to develop chronic back pain, and dropping the habit may cut your chances of developing this often debilitating condition. [More]

Women with bad backs have renewed hope for better sex lives

Newly published findings from the University of Waterloo are giving women with bad backs renewed hope for better sex lives. The findings—part of the first-ever study to document how the spine moves during sex—outline which sex positions are best for women suffering from different types of low-back pain. The new recommendations follow on the heels of comparable guidelines for men released last month. [More]
Qualified massage therapist can play key role in improving cardiovascular health

Qualified massage therapist can play key role in improving cardiovascular health

Many already view massage as an important approach to relieving muscle pain or as a means to relax. However, working with a qualified massage therapist can also play a significant role in improving cardiovascular health as evidenced by a growing body of research, according to the American Massage Therapy Association. [More]
Bone mineral density not linked to musculoskeletal pain

Bone mineral density not linked to musculoskeletal pain

Bone mineral density does not contribute to musculoskeletal pain, researchers report in findings that shed light on the controversy over whether osteoporosis is a painless disease. [More]
Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. [More]
Poor body mechanics cause chronic lower back pain

Poor body mechanics cause chronic lower back pain

If you want to steer clear of lower back pain, remember this: Arch is good, flat is bad. [More]
AAN releases new position statement on opioids for chronic non-cancer pain

AAN releases new position statement on opioids for chronic non-cancer pain

According to a new position statement from the American Academy of Neurology, the risk of death, overdose, addiction or serious side effects with prescription opioids outweigh the benefits in chronic, non-cancer conditions such as headache, fibromyalgia and chronic low back pain. [More]